RxDoctor Payments DataLook up a doctor →

Sejal Lauro, PA

Medical · Jefferson Valley, NYNPI 1215024898

Payments from drug & device makers

$26,463in general payments, 2019–2025

Across 1,226 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • AstraZeneca$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Novo Nordisk$2K
  • Bayer$1K
  • Lilly USA, LLC$1K
  • plus $10K from 45 others

What the payments were for

  • Food & beverage$26,25399%
  • Education$2101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,463 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$180,071
Medicare patients
289
Services billed
4,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban53$74,020
MounjaroTirzepatide63$73,317
EliquisApixaban49$66,670
OzempicSemaglutide44$57,320
JardianceEmpagliflozin34$51,391
Dihydroergotamine Mesylate19$41,974
FarxigaDapagliflozin Propanediol26$39,135
VraylarCariprazine Hcl11$26,087
LinzessLinaclotide18$20,542
TradjentaLinagliptin28$19,949
CreonLipase/Protease/Amylase13$18,140
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$9,403
PaxlovidNirmatrelvir/Ritonavir17$4,080
Nebivolol Hcl40$2,742
Omeprazole143$2,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$348$74,02053 claims
Lilly USA, LLCMounjaro$1,435$73,31763 claims
Boehringer IngelheimJardiance, Tradjenta$917$71,33962 claims
PfizerEliquis, Paxlovid$989$70,75066 claims
AbbVieVraylar, Linzess, Creon, Synthroid$6,759$66,79570 claims
Novo NordiskOzempic$1,859$57,32044 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,738$48,53838 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$41$2,317125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.

Other medical in Jefferson Valley

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →